Client Communications - Prime Therapeutics

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Who we are
Our solutions
News & insights
Pharmacy
Careers

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Home
Client Communication
Client Communications Hub
Client Communications

Explore what's trending at Prime

https://www.primetherapeutics.com/w/prime-perspectives-webcast-lowest-net-cost-and-point-of-sale-rebates Example Link

Client news

Understanding Lowest Net Cost and Point-of-Sale Rebate Opportunities

August 10, 2026

https://www.primetherapeutics.com/w/upcoming-key-dates-and-deadlines-for-peak-season-1 Example Link

Client news

Upcoming key dates and deadlines for peak season

October 01, 2026

https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support Example Link

Client news

Gag Clause Prohibition Compliance Attestation support

September 15, 2026

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment Example Link

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

The Latest

Categories

CC Sub-Categories

https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support

Client news

Gag Clause Prohibition Compliance Attestation support

September 15, 2026

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance

Client news

Prime’s approach to Mental Health Parity compliance

September 08, 2026

https://www.primetherapeutics.com/w/upcoming-key-dates-and-deadlines-for-peak-season https://www.primetherapeutics.com/w/upcoming-key-dates-and-deadlines-for-peak-season

Client news

Upcoming key dates and deadlines for peak season

September 01, 2026

https://www.primetherapeutics.com/w/pcma-announces-drug-pricing-transparency-commitment-with-trumprx https://www.primetherapeutics.com/w/pcma-announces-drug-pricing-transparency-commitment-with-trumprx

Client news

PCMA announces drug pricing transparency commitment with TrumpRx

August 14, 2026

https://www.primetherapeutics.com/w/prime-perspectives-webcast-lowest-net-cost-and-point-of-sale-rebates https://www.primetherapeutics.com/w/prime-perspectives-webcast-lowest-net-cost-and-point-of-sale-rebates

Client news

Understanding Lowest Net Cost and Point-of-Sale Rebate Opportunities

August 10, 2026

https://www.primetherapeutics.com/w/update-on-department-of-labor-transparency-rule https://www.primetherapeutics.com/w/update-on-department-of-labor-transparency-rule

Client news

Update on Department of Labor transparency rule

August 10, 2026

https://www.primetherapeutics.com/w/prime-perspectives-webcast-prime-s-humira-stelara-biosimilar-strategy https://www.primetherapeutics.com/w/prime-perspectives-webcast-prime-s-humira-stelara-biosimilar-strategy

Client news

Navigating Humira® & Stelara® Biosimilar Adoption Strategies

August 06, 2026

https://www.primetherapeutics.com/w/prime-perspectives-webcast-glp-1-solutions https://www.primetherapeutics.com/w/prime-perspectives-webcast-glp-1-solutions

Client news

GLP-1 Solutions: Resources to Support Your 2027 Benefit Strategy

July 29, 2026

Showing 1 to 9 of 184

Categories

CC Sub-Categories

https://www.primetherapeutics.com/w/upcoming-key-dates-and-deadlines-for-peak-season-1 https://www.primetherapeutics.com/w/upcoming-key-dates-and-deadlines-for-peak-season-1

Client news

Upcoming key dates and deadlines for peak season

October 01, 2026

https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support

Client news

Gag Clause Prohibition Compliance Attestation support

September 15, 2026

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance

Client news

Prime’s approach to Mental Health Parity compliance

September 08, 2026

https://www.primetherapeutics.com/w/important-medicare-part-d-notifications-support-for-plan-sponsors https://www.primetherapeutics.com/w/important-medicare-part-d-notifications-support-for-plan-sponsors

Client news

Important Medicare Part D notifications support for plan sponsors

September 03, 2026

Client news

PCMA announces drug pricing transparency commitment with TrumpRx

August 14, 2026

https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness

Client news

Q2 NCPDP F6 project update - execution and readiness

July 23, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-july-2026 https://www.primetherapeutics.com/w/featured-drug-insights-july-2026

Client news

Featured Drug Insights: July 2026

July 20, 2026

https://www.primetherapeutics.com/w/cgm-criteria-and-management-updates https://www.primetherapeutics.com/w/cgm-criteria-and-management-updates

Client news

CGM criteria and management updates

July 02, 2026

Showing 1 to 9 of 134

Categories

CC Sub-Categories

https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support https://www.primetherapeutics.com/w/gag-clause-prohibition-compliance-attestation-support

Client news

Gag Clause Prohibition Compliance Attestation support

September 15, 2026

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance

Client news

Prime’s approach to Mental Health Parity compliance

September 08, 2026

Client news

Important Medicare Part D notifications support for plan sponsors

September 03, 2026

Client news

PCMA announces drug pricing transparency commitment with TrumpRx

August 14, 2026

https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness

Client news

Q2 NCPDP F6 project update - execution and readiness

July 23, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-july-2026 https://www.primetherapeutics.com/w/featured-drug-insights-july-2026

Client news

Featured Drug Insights: July 2026

July 20, 2026

https://www.primetherapeutics.com/w/cgm-criteria-and-management-updates https://www.primetherapeutics.com/w/cgm-criteria-and-management-updates

Client news

CGM criteria and management updates

July 02, 2026

https://www.primetherapeutics.com/w/formulary-updates-notice-1 https://www.primetherapeutics.com/w/formulary-updates-notice-1

Client news

View the latest formulary updates notice

July 01, 2026

Showing 1 to 9 of 146

Categories

CC Sub-Categories

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance

Client news

Prime’s approach to Mental Health Parity compliance

September 08, 2026

Client news

PCMA announces drug pricing transparency commitment with TrumpRx

August 14, 2026

https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness

Client news

Q2 NCPDP F6 project update - execution and readiness

July 23, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-july-2026 https://www.primetherapeutics.com/w/featured-drug-insights-july-2026

Client news

Featured Drug Insights: July 2026

July 20, 2026

https://www.primetherapeutics.com/w/prime-s-response-to-cms-proposed-pa-reforms-for-prescription-drugs https://www.primetherapeutics.com/w/prime-s-response-to-cms-proposed-pa-reforms-for-prescription-drugs

Client news

Prime's response to CMS proposed PA reforms for prescription drugs

June 30, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-june-2026 https://www.primetherapeutics.com/w/featured-drug-insights-june-2026

Client news

Featured Drug Insights: June 2026

June 15, 2026

https://www.primetherapeutics.com/w/tennessee-sb-2040-overview-and-next-steps https://www.primetherapeutics.com/w/tennessee-sb-2040-overview-and-next-steps

Client news

Tennessee SB 2040: Overview and next steps

May 08, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-may-2026 https://www.primetherapeutics.com/w/featured-drug-insights-may-2026

Client news

Featured Drug Insights: May 2026

May 06, 2026

Showing 1 to 9 of 98

Categories

CC Sub-Categories

https://www.primetherapeutics.com/w/prime-announces-chief-financial-officer-appointment Example Link

Client news

Prime announces Chief Financial Officer appointment

September 10, 2026

https://www.primetherapeutics.com/w/prime-s-approach-to-mental-health-parity-compliance Example Link

Client news

Prime’s approach to Mental Health Parity compliance

September 08, 2026

https://www.primetherapeutics.com/w/pcma-announces-drug-pricing-transparency-commitment-with-trumprx Example Link

Client news

PCMA announces drug pricing transparency commitment with TrumpRx

August 14, 2026

https://www.primetherapeutics.com/w/q2-ncpdp-f6-project-update-execution-and-readiness Example Link

Client news

Q2 NCPDP F6 project update - execution and readiness

July 23, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-july-2026 Example Link

Client news

Featured Drug Insights: July 2026

July 20, 2026

https://www.primetherapeutics.com/w/prime-s-response-to-cms-proposed-pa-reforms-for-prescription-drugs Example Link

Client news

Prime's response to CMS proposed PA reforms for prescription drugs

June 30, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-june-2026 Example Link

Client news

Featured Drug Insights: June 2026

June 15, 2026

https://www.primetherapeutics.com/w/featured-drug-insights-may-2026 Example Link

Client news

Featured Drug Insights: May 2026

May 06, 2026

https://www.primetherapeutics.com/w/read-featured-drug-insights-april-2026 Example Link

Client news

Featured Drug Insights: April 2026

April 13, 2026

Showing 1 to 9 of 105

Login Portals

Members and Consumers
Clients and Health Plans
Pharmacy + Provider Resources

Compliance / Legal

Privacy Policy
Notice of Privacy Practices
Terms of Use
Nondiscrimination + Languages
Subrogation

Company

About us
Careers
Media

About us

Corporate social responsibility

Solutions overview

Modern technology

Drug access

Clinical solutions

Condition management

Specialty drug management

Government solutions

Single-state programs

Home Delivery

Specialty Pharmacy

Navigate to

Back

Back

Back

Explore what's trending at Prime

Understanding Lowest Net Cost and Point-of-Sale Rebate Opportunities

Upcoming key dates and deadlines for peak season

Gag Clause Prohibition Compliance Attestation support

Prime announces Chief Financial Officer appointment

The Latest

Gag Clause Prohibition Compliance Attestation support

Prime announces Chief Financial Officer appointment

Prime’s approach to Mental Health Parity compliance

Upcoming key dates and deadlines for peak season

PCMA announces drug pricing transparency commitment with TrumpRx

Understanding Lowest Net Cost and Point-of-Sale Rebate Opportunities

Update on Department of Labor transparency rule

Navigating Humira® & Stelara® Biosimilar Adoption Strategies

GLP-1 Solutions: Resources to Support Your 2027 Benefit Strategy

Upcoming key dates and deadlines for peak season

Gag Clause Prohibition Compliance Attestation support

Prime announces Chief Financial Officer appointment

Prime’s approach to Mental Health Parity compliance

Important Medicare Part D notifications support for plan sponsors

PCMA announces drug pricing transparency commitment with TrumpRx

Q2 NCPDP F6 project update - execution and readiness

Featured Drug Insights: July 2026

CGM criteria and management updates

Gag Clause Prohibition Compliance Attestation support

Prime announces Chief Financial Officer appointment

Prime’s approach to Mental Health Parity compliance

Important Medicare Part D notifications support for plan sponsors

PCMA announces drug pricing transparency commitment with TrumpRx

Q2 NCPDP F6 project update - execution and readiness

Featured Drug Insights: July 2026

CGM criteria and management updates

View the latest formulary updates notice

Prime announces Chief Financial Officer appointment

Prime’s approach to Mental Health Parity compliance

PCMA announces drug pricing transparency commitment with TrumpRx

Q2 NCPDP F6 project update - execution and readiness

Featured Drug Insights: July 2026

Prime's response to CMS proposed PA reforms for prescription drugs

Featured Drug Insights: June 2026

Tennessee SB 2040: Overview and next steps

Featured Drug Insights: May 2026

Prime announces Chief Financial Officer appointment

Prime’s approach to Mental Health Parity compliance

PCMA announces drug pricing transparency commitment with TrumpRx

Q2 NCPDP F6 project update - execution and readiness

Featured Drug Insights: July 2026

Prime's response to CMS proposed PA reforms for prescription drugs

Featured Drug Insights: June 2026

Featured Drug Insights: May 2026

Featured Drug Insights: April 2026

Login Portals

Compliance / Legal

Company